Effect of the human papillomavirus vaccine on the risk of genital warts: a nationwide cohort study of Korean adolescent girls
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
OBJECTIVES The purpose of this study was to assess the effectiveness of human papillomavirus (HPV) vaccination administered to adolescent girls through Korea’s National Immunization Program. METHODS This retrospective cohort study included patients who were 12-13 years old, whether vaccinated or unvaccinated, between July 2016 and December 2017. The incidence of genital warts (GWs) was monitored through 2021. Time-stratified hazard ratios (HRs) were estimated, adjusting for birth year, socioeconomic status, and the level of urbanization of the region, and were presented with 95% confidence intervals (CIs). Data were sourced from the Immunization Registry Integration System, linked with the National Health Information Database. RESULTS The study included 332,062 adolescent girls, with an average follow-up period of approximately 4.6 years. Except for the first year, the HRs for the vaccinated group were lower than those for the unvaccinated group. The HRs for specific cut-off years were as follows: year 2, 0.62 (95% CI, 0.31 to 1.13); year 3, 0.58 (95% CI, 0.35 to 0.96); and year 4 and beyond, 0.39 (95% CI, 0.28 to 0.52). CONCLUSIONS Our findings indicate that HPV vaccination was associated with a reduction in the risk of GWs among adolescent girls. Notably, this reduction became significant as the incidence of GWs increased with age.
Abstract
OBJECTIVES The purpose of this study was to assess the effectiveness of human papillomavirus (HPV) vaccination administered to adolescent girls through Korea’s National Immunization Program. METHODS This retrospective cohort study included patients who were 12-13 years old, whether vaccinated or unvaccinated, between July 2016 and December 2017. The incidence of genital warts (GWs) was monitored through 2021. Time-stratified hazard ratios (HRs) were estimated, adjusting for birth year, socioeconomic status, and the level of urbanization of the region, and were presented with 95% confidence intervals (CIs). Data were sourced from the Immunization Registry Integration System, linked with the National Health Information Database. RESULTS The study included 332,062 adolescent girls, with an average follow-up period of approximately 4.6 years. Except for the first year, the HRs for the vaccinated group were lower than those for the unvaccinated group. The HRs for specific cut-off years were as follows: year 2, 0.62 (95% CI, 0.31 to 1.13); year 3, 0.58 (95% CI, 0.35 to 0.96); and year 4 and beyond, 0.39 (95% CI, 0.28 to 0.52). CONCLUSIONS Our findings indicate that HPV vaccination was associated with a reduction in the risk of GWs among adolescent girls. Notably, this reduction became significant as the incidence of GWs increased with age.
참고문헌 (29)
- "Cervical cancer"[URL]
- Garland SM, "Impact and effectiveness of the quadrivalent human papillomavirus vaccine : a systematic review of 10 years of real-world experience", Clin Infect Dis, 63, pp.519~527 (2016)[DOI]
- "Clinical overview: genital warts" (2022)[URL]
- Workowski KA, "Sexually transmitted infections treatment guidelines, 2021", MMWR Recomm Rep, 70, pp.1~187 (2021)[DOI]
- Swygard H, "Goldman-Cecil medicine", pp.1841~1845 (2024), Elsevier
- Gilson R, "2019 IUSTI-Europe guideline for the management of anogenital warts", J Eur Acad Dermatol Venereol, 34, pp.1644~1653 (2020)[DOI]
- Yanofsky VR, "Genital warts : a comprehensive review", J Clin Aesthet Dermatol, 5, pp.25~36 (2012)
- Flagg EW, "Declines in anogenital warts among age groups most likely to be impacted by human papillomavirus vaccination, United States, 2006-2014", Am J Public Health, 108, pp.112~119 (2018)[DOI]
- Chow EP, "Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus(HPV)vaccination programme", Sex Transm Infect, 91, pp.214~219 (2015)[DOI]
- Bauer HM, "Evidence of human papillomavirus vaccine effectiveness in reducing genital warts : an analysis of California public family planning administrative claims data, 2007-2010", Am J Public Health, 102, pp.833~835 (2012)[DOI]
- Dominiak-Felden G, "Evaluating the early benefit of quadrivalent HPV vaccine on genital warts in Belgium : a cohort study", PLoS One, 10, pp.e0132404~ (2015)[DOI]
- Mikolajczyk RT, "Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany-an ecologic study", Sex Transm Dis, 40, pp.28~31 (2013)[DOI]
- Drolet M, "Population-level impact and herd effects following human papillomavirus vaccination programmes : a systematic review and meta-analysis", Lancet Infect Dis, 15, pp.565~580 (2015)[DOI]
- Report of the evaluation for validity of discharged diagnoses in Korean Health Insurance database, "Park E", Health Insurance Review and Assessment Service, ~ (2017)
- Kraut AA, "Incidence of anogenital warts in Germany : a population-based cohort study", BMC Infect Dis, 10, pp.360~ (2010)[DOI]
- Ki M, "The economic burden of human papillomavirus infection-associated diseases in the Republic of Korea, 2002-2015", Vaccine, 36, pp.4633~4640 (2018)[DOI]
- Muñoz-Quiles C, "Human papillomavirus vaccines effectiveness to prevent genital warts : a population-based study using health system integrated databases, 2009-2017", Vaccine, 40, pp.316~324 (2022)[DOI]
- Dekker FW, "Survival analysis : time-dependent effects and time-varying risk factors", Kidney Int, 74, pp.994~997 (2008)[DOI]
- FUTURE I, "II Study Group", Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts : randomised controlled trial, 2010, pp.341, c3493~
- Brotons M, "Impact of a single-age cohort human papillomavirus vaccination strategy in Catalonia, Spain : population-based analysis of anogenital warts in men and women", Prev Med, 138, pp.106166~ (2020)[DOI]
- Drolet M, "Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes : updated systematic review and meta-analysis", Lancet, 394, pp.497~509 (2019)[DOI]
- Fairley CK, "Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women", Sex Transm Infect, 85, pp.499~502 (2009)[DOI]
- Yoon D, "Association between human papillomavirus vaccination and serious adverse events in South Korean adolescent girls : nationwide cohort study", BMJ, 372, pp.m4931~ (2021)[DOI]
- Kim JA, "Towards actualizing the value potential of Korea Health Insurance Review and Assessment(HIRA)data as a resource for health research : strengths, limitations, applications, and strategies for optimal use of HIRA data", J Korean Med Sci, 32, pp.718~728 (2017)[DOI]
- Park JS, "Clinical study using healthcare claims database", J Rheum Dis, 28, pp.119~125 (2021)[DOI]
- O’Malley KJ, "Measuring diagnoses : ICD code accuracy", Health Serv Res, 40, pp.1620~1639 (2005)[DOI]
- Smith PJ, "Children who have received no vaccines : who are they and where do they live", Pediatrics, 114, pp.187~195 (2004)
- Shim Jl, "Factors influencing intention for human papillomavirus vaccination among parents with elementary school girls", J Korean Acad Soc Nurs Educ, 23, pp.367~377 (2017)[DOI]
- Clinical recommendation for cervical cancer prevention vaccine Gardasil, 2011, "Korean Society of Gynecologic Oncology", Korean Society of Gynecologic Oncology, ~ (2011)